TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro

Antiviral Therapy

Volumn 10, Issue 8, 2005, Pages 967-968

  Tremblay, Cécile L ^a,d   Giguel, Françoise ^a   Chou, Ting Chao ^b   Dong, Huajin ^e   Takashima, Katsunori ^c   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; EFAVIRENZ PLUS INDINAVIR; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAK 652; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LETTER; PRIORITY JOURNAL;

ANTI-RETROVIRAL AGENTS; CELLS, CULTURED; DRUG SYNERGISM; HIV-1; IMIDAZOLES; RECEPTORS, CCR5;

EID: 30444455633     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M & Iizawa Y. TAK-652 inhibits CCR5-mediated HIV-1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrobial Agents and Chemotherapy. In the press.
2. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy, 1991; pp. 61-102. Edited by TC Chou & DC Rideout. San Diego, CA: Academic Press.
3. Chou TC & Martin N. 2004. CompuSyn for Windows, Multiple-Drug Dose-Effect Analyzer and Manual. Combosyn, Paramus, NJ, USA.
4. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM & Hirsch MS. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrobial Agents and Chemotherapy 2002; 46:1336-1339.
5. Tremblay C. Effects of HIV-1 entry inhibitors in combination. Current Pharmaceutical Design 2004; 10:1861-1865.
6. Tremblay CL, Giguel F, Guan Y, Chou TC, Takashima K & Hirsch MS. TAK-220, a novel small molecule CCR5 antagonist, has favorable anti-HIV interactions with other antiretrovirals in vitro. Antimicrobial Agents and Chemotherapy 2005; 49:3483-3485.
7. Tremblay C, Kollmann C, Giguel F, Chou TC & Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. Journal of Acquired Immune Deficiency Syndrome 2000; 25:99-102.